CL2017000309A1 - Indoles para su uso en la infección por el virus de la gripe - Google Patents

Indoles para su uso en la infección por el virus de la gripe

Info

Publication number
CL2017000309A1
CL2017000309A1 CL2017000309A CL2017000309A CL2017000309A1 CL 2017000309 A1 CL2017000309 A1 CL 2017000309A1 CL 2017000309 A CL2017000309 A CL 2017000309A CL 2017000309 A CL2017000309 A CL 2017000309A CL 2017000309 A1 CL2017000309 A1 CL 2017000309A1
Authority
CL
Chile
Prior art keywords
indoles
influenza virus
virus infection
flu
infection
Prior art date
Application number
CL2017000309A
Other languages
English (en)
Spanish (es)
Inventor
Gowan David Craig Mc
Pierre Jean-Marie Bernard Raboisson
Werner Constant Johan Embrechts
Tim Hugo Maria Jonckers
Jerôme Emile Georges Guillemont
Ludwig Paul Cooymans
Antoine Benjamin Michaut
Original Assignee
Janssen Sciences Ireland Uc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Sciences Ireland Uc filed Critical Janssen Sciences Ireland Uc
Publication of CL2017000309A1 publication Critical patent/CL2017000309A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/16Antivirals for RNA viruses for influenza or rhinoviruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CL2017000309A 2014-08-08 2017-02-07 Indoles para su uso en la infección por el virus de la gripe CL2017000309A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP14180331 2014-08-08

Publications (1)

Publication Number Publication Date
CL2017000309A1 true CL2017000309A1 (es) 2017-08-18

Family

ID=51298610

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017000309A CL2017000309A1 (es) 2014-08-08 2017-02-07 Indoles para su uso en la infección por el virus de la gripe

Country Status (18)

Country Link
US (1) US10597390B2 (cg-RX-API-DMAC7.html)
EP (1) EP3177609A1 (cg-RX-API-DMAC7.html)
JP (1) JP6577570B2 (cg-RX-API-DMAC7.html)
KR (1) KR102488479B1 (cg-RX-API-DMAC7.html)
CN (1) CN106573920B (cg-RX-API-DMAC7.html)
AU (1) AU2015298876B2 (cg-RX-API-DMAC7.html)
BR (1) BR112017002370B1 (cg-RX-API-DMAC7.html)
CA (1) CA2954751C (cg-RX-API-DMAC7.html)
CL (1) CL2017000309A1 (cg-RX-API-DMAC7.html)
EA (1) EA201790266A1 (cg-RX-API-DMAC7.html)
IL (1) IL250408B (cg-RX-API-DMAC7.html)
MA (1) MA40547A (cg-RX-API-DMAC7.html)
MX (1) MX381488B (cg-RX-API-DMAC7.html)
PH (1) PH12017500207B1 (cg-RX-API-DMAC7.html)
SG (1) SG11201700956VA (cg-RX-API-DMAC7.html)
UA (1) UA124609C2 (cg-RX-API-DMAC7.html)
WO (1) WO2016020526A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201700952B (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2442809T3 (pl) 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
SG11201700956VA (en) 2014-08-08 2017-03-30 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
WO2016183120A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP6704416B2 (ja) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドVertex Pharmaceuticals Incorporated インフルエンザウイルスの複製の阻害剤を調製する方法
US10717732B2 (en) 2015-12-09 2020-07-21 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
EA201891576A1 (ru) * 2016-01-07 2018-11-30 Янссен Сайенсиз Айрлэнд Юси Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
WO2017133670A1 (en) * 2016-02-05 2017-08-10 Savira Pharmaceuticals Gmbh Pyridine and pyrimidine derivatives and their use in treatment, amelioration or prevention of influenza
CN107759571B (zh) * 2016-08-16 2021-03-02 广东东阳光药业有限公司 流感病毒复制抑制剂及其使用方法和用途
WO2018041091A1 (en) * 2016-08-30 2018-03-08 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication, application methods and uses thereof
CN109790159B (zh) 2016-09-05 2020-01-14 广东众生睿创生物科技有限公司 抗流感病毒嘧啶衍生物
KR102554019B1 (ko) 2016-12-15 2023-07-11 선샤인 레이크 파르마 컴퍼니 리미티드 인플루엔자 바이러스 복제의 억제제 및 이의 용도
WO2018119395A1 (en) * 2016-12-23 2018-06-28 Aquinnah Pharmaceuticals, Inc. Compouns, compositions and methods of use
CN108276401B (zh) 2017-01-05 2020-12-22 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
CN108727369B (zh) * 2017-04-25 2023-06-09 广东东阳光药业有限公司 流感病毒复制抑制剂及其用途
TWI794433B (zh) * 2018-03-05 2023-03-01 大陸商廣東衆生睿創生物科技有限公司 吡啶并吡唑類化合物的晶型、鹽型及其製備方法
JP7450017B2 (ja) 2019-07-22 2024-03-14 広東衆生睿創生物科技有限公司 ピリミジン誘導体の優位な塩形およびその結晶形
CN113045475A (zh) * 2019-12-27 2021-06-29 上海泓博智源医药股份有限公司 一种5-溴-7-甲基吲哚的制备方法
CA3185649A1 (en) * 2020-07-20 2022-01-27 Bakary-Barry Toure Indole compounds as androgen receptor modulators
EP4214201A4 (en) * 2020-09-18 2024-10-09 Sunshine Lake Pharma Co., Ltd. PROCESS FOR THE PREPARATION OF SUBSTITUTED PYRIMIDINE PIPERAZINE COMPOUNDS
PE20251586A1 (es) * 2022-10-12 2025-06-16 Maze Therapeutics Inc Inhibidores del miembro 19 de la familia de portadores de solutos 6a (slc6a19) y metodos de uso de los mismos

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2332940T3 (pl) 2004-03-30 2013-03-29 Vertex Pharma Azaindole użyteczne jako inhibitory JAK i innych kinaz białkowych
TWI424999B (zh) 2006-01-17 2014-02-01 Vertex Pharma 適合作為傑納斯激酶(janus kinase)抑制劑之氮雜吲哚
PL2442809T3 (pl) * 2009-06-17 2017-02-28 Vertex Pharmaceuticals Incorporated Inhibitory replikacji wirusów grypy
JP5876051B2 (ja) * 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
AU2011343642A1 (en) * 2010-12-16 2013-05-02 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
KR20130128435A (ko) * 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 인플루엔자 바이러스 복제의 억제제
UA118010C2 (uk) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
MX359032B (es) 2011-09-01 2018-09-12 Hoffmann La Roche Inhibidores de pirrolopirazina cinasa.
WO2013184985A1 (en) * 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
LT3068776T (lt) 2013-11-13 2019-08-12 Vertex Pharmaceuticals Incorporated Gripo virusų replikacijos inhibitoriai
SG11201700956VA (en) 2014-08-08 2017-03-30 Janssen Sciences Ireland Uc Indoles for use in influenza virus infection
UY36255A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos por halógeno novedosos
UY36249A (es) 2014-08-08 2016-01-29 Bayer Cropscience Ag Compuestos sustituidos con halógeno novedosos
CN104592038A (zh) 2015-01-12 2015-05-06 烟台万润精细化工股份有限公司 一种5,5-二甲基-1,3-环己二胺的制备方法

Also Published As

Publication number Publication date
CN106573920B (zh) 2020-11-10
EP3177609A1 (en) 2017-06-14
BR112017002370B1 (pt) 2022-11-22
ZA201700952B (en) 2018-12-19
BR112017002370A2 (pt) 2017-12-05
KR102488479B1 (ko) 2023-01-12
MX381488B (es) 2025-03-12
CA2954751C (en) 2023-01-17
IL250408B (en) 2020-08-31
US20170226102A1 (en) 2017-08-10
JP6577570B2 (ja) 2019-09-18
EA201790266A1 (ru) 2017-06-30
KR20170039275A (ko) 2017-04-10
IL250408A0 (en) 2017-03-30
SG11201700956VA (en) 2017-03-30
US10597390B2 (en) 2020-03-24
CN106573920A (zh) 2017-04-19
AU2015298876B2 (en) 2020-02-13
UA124609C2 (uk) 2021-10-20
PH12017500207A1 (en) 2017-07-10
CA2954751A1 (en) 2016-02-11
JP2017523225A (ja) 2017-08-17
AU2015298876A1 (en) 2017-02-02
MX2017001752A (es) 2018-02-08
PH12017500207B1 (en) 2017-07-10
MA40547A (fr) 2017-06-14
WO2016020526A1 (en) 2016-02-11

Similar Documents

Publication Publication Date Title
CL2017000309A1 (es) Indoles para su uso en la infección por el virus de la gripe
CL2017000533A1 (es) Pirrolopirimidinas para uso en la infección por el virus de la gripe
CL2018001960A1 (es) Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza.
CL2016001120A1 (es) Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct
UY37252A (es) Compuestos para el tratamiento de infección por virus de la hepatitis b
CL2016000424A1 (es) Métodos y composiciones para el arn-guiado tratamiento de la infección por vih
CL2016000493A1 (es) Inhibidores de polimerasa hcv.
CL2014001956A1 (es) Compuestos derivados de beta-lactamicos sustituidos con amidina; metodo para su preparacion; medicamento que los comprende; y su uso para el tratamiento y/o profilaxis de infecciones bacterianas.
CL2013003019A1 (es) Compuestos derivados de benzotiazol; composicion farmaceutica que los comprende; y su uso en el tratamiento del vih.
DOP2016000336A (es) Derivados de isoindolina para uso en el tratamiento de una infeccion viral
MX2017008720A (es) Derivados y metodos para tratamiento de las infecciones por hepatitis b.
CR20150337A (es) Derivados de pirimidinona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral
CL2014002093A1 (es) Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas.
CL2015003615A1 (es) Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
CL2015001864A1 (es) Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih.
CL2015002335A1 (es) Derivados de 2-aminopirimidina para el tratamiento de infecciones víricas.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CL2016002835A1 (es) “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct
MX2017003205A (es) Composiciones antimicrobianas y sus metodos de uso.
CL2017001483A1 (es) Formulación de relación fija de insulina glargina/lixisenatida
CL2017000152A1 (es) Derivados de isoindolinona
CL2016002879A1 (es) Composiciones farmacéuticas para tratar enfermedades infecciosas
EA201891576A1 (ru) Функционализированные пентановые кислоты для применения при инфекциях, вызванных вирусом гриппа
PE20150167A1 (es) (r)-nifuratel, su uso para el tratamiento de las infecciones y sintesis de (r) y (s)-nifuratel
CL2017002803A1 (es) Compuestos heterocíclicos y su uso en la prevención o tratamiento de las infecciones bacterianas